BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Hikma Pharmaceuticals Expands in Egypt With $22 Million Acquisition


1/10/2013 8:07:25 AM

Fast-growing Jordan-headquartered drugmaker Hikma Pharmaceuticals (LSE: HIK) says it has agreed to acquire the Egyptian Company for Pharmaceuticals & Chemical Industries (EPCI) from a consortium of shareholders. Hikma will pay an aggregate cash consideration of 142.4 million Egyptian pounds (around $22.2 million) on closing, which is expected before February 14, 2013. According to Hikma, the acquisition of EPCI: Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here. • strengthens the firm’s position in the large and fast growing Egyptian market; • adds a complementary portfolio of 35 products in 46 dosage forms and strengths, including three original cephalosporin anti-infective brands for the Egyptian market; • enhances Hikma’s portfolio in key therapeutic areas such as cephalosporin anti–infectives, central nervous system and alimentary tract and provides entry into the ophthalmology market; • adds a dedicated cephalosporin facility and an additional general formulation manufacturing plant in Egypt; and • leverages Hikma’s established market position in Egypt and strong sales and marketing team. The Egyptian pharmaceutical market is one of the largest and fastest growing Middle East and North Africa (MENA) markets. According to IMS Health, the private retail market is valued at around $2.3 billion and grew by 10.6% in the 12 months to June 2012. With a population of approximately 84 million people, the Egyptian market offers excellent growth opportunities. Hikma Egypt is currently the seventeenth largest pharmaceutical manufacturer in Egypt, with an estimated market share of 1.6%.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->